ViroCell Biologics
Private Company
Funding information not available
Overview
ViroCell Biologics is an innovation-driven viral vector CDMO founded in 2020 and based in London. Unlike broader CDMOs, it specializes in lentiviral and retroviral vectors, offering end-to-end services from vector design and process development to GMP manufacturing for clinical trials. The company leverages over 25 years of collective team experience in designing complex vectors to accelerate the development of cell and gene therapies, primarily in oncology and infectious diseases. Its core differentiator is a deep scientific focus on vector design and optimization to improve performance, safety, and yield for its clients.
Technology Platform
Specialized platform for the design, optimization, process development, and GMP manufacturing of lentiviral and retroviral vectors. Leverages a proprietary vector backbone portfolio and a streamlined production process aimed at de-risking and accelerating client cell and gene therapy programs.
Opportunities
Risk Factors
Competitive Landscape
ViroCell competes with large, diversified CDMOs (e.g., Lonza, Catalent, Thermo Fisher) that offer viral vector services among many others, as well as with other specialized viral vector CDMOs (e.g., Oxford Biomedica, BioNTech). Its differentiation lies in its exclusive focus on lentiviral/retroviral vectors, deep design expertise, and a collaborative model tailored for early-phase development.